See your cannabis & CBD results in Decode
A real preview of how your CYP enzyme genetics relate to THC metabolism, CBD processing, and drug interactions from smoked cannabis — with the strength of the evidence stated for each.
Your Cannabis & CBD Results
Inside Decode — sample preview
How your CYP enzyme genetics affect THC and CBD metabolism
Your Cannabis Metabolism Summary
4 Genes ReportedYour results cover 4 genes involved in how your body processes cannabis and CBD, each with the published research behind it and what that research does — and does not — establish.
THC Metabolism Profile — CYP2C9
One Reduced-Function CYP2C9 Copy
CYP2C9: *1/*3 (Intermediate Metabolizer)
You carry one normal-function copy of CYP2C9 and one copy of the reduced-function *3 variant. CYP2C9 is the primary enzyme that converts THC into its main active metabolite, 11-OH-THC.
Clinical Context
In 43 healthy volunteers given oral THC, people with two copies of *3 had a median total THC exposure roughly 3 times higher than people with two normal-function copies, along with a trend toward greater sedation; the *2 variant made no difference. That study's clear finding was in people with two reduced-function copies, so the effect of carrying a single copy, as here, is less certain. FDA labeling for dronabinol reflects a 2- to 3-fold exposure difference in people with diminished CYP2C9 function.
What This Means for You
- This describes average differences between genotype groups, not a prediction for you.
- Dose, product, food, absorption and tolerance all affect response alongside genetics.
- Mention this result to your healthcare provider if using medical cannabis.
Additional Findings
One Reduced-Function CYP2C19 Copy
CYP2C19: *1/*2
You carry one normal-function copy of CYP2C19 and one copy of the reduced-function *2 variant. CBD is metabolized primarily by CYP2C19 and CYP3A4, with CYP2C19 the main route to the active metabolite 7-OH-CBD.
Full analysis, clinical context, and recommendations in Decode
CYP3A5 + CYP2C19 Genotype Context
CYP3A5: *3/*3
You have the genotype combination examined in a 2026 study of CBD-related diarrhea. This is context on that research — it is not a prediction that CBD will cause you side effects.
Full analysis, clinical context, and recommendations in Decode
Higher CYP1A2 Inducibility — Smoked Cannabis Interaction
CYP1A2: rs762551 (A/A)
Your CYP1A2 genotype (rs762551 A/A) is associated with higher enzyme inducibility. Smoked cannabis — but not vaped or edible forms — is thought to induce CYP1A2 through combustion byproducts rather than through cannabinoids themselves.
Full analysis, clinical context, and recommendations in Decode
3 additional sections including CBD metabolism, your CYP3A5 + CYP2C19 genotype context, and smoked cannabis drug interactions in Decode
Limitations
- Cannabis pharmacogenomics is an evolving field with fewer clinical trials than pharmaceutical PGx.
- Decode does not predict whether CBD will cause side effects. The only study linking CYP3A5 and CYP2C19 genotype to CBD-related diarrhea is a secondary analysis of 33 healthy volunteers on prescription-strength doses; it could not separate the two genes, claimed no causal relationship, and its authors concluded that pharmacogenomic testing may hold questionable utility for predicting such events.
- Consumer genotyping chips test a limited set of variants per gene.
- Individual response to cannabis depends on many factors beyond genetics.
- These results are for educational and informational purposes only.
- Decode does not recommend or endorse cannabis use.
This is a sample built from fictional data for demonstration purposes. Your own results in Decode reflect your personal genetics.
Decode your own cannabis & CBD response
Upload your 23andMe or AncestryDNA raw data. See your genome overview free; unlock your cannabis & CBD results with a one-time $59 — yours for life.
Get Started FreeFree vs Decode
Create your account and see your genome overview free. Decode maps your CYP2C9, CYP2C19, CYP3A5, and CYP1A2 results to cannabis-specific metabolism and drug interactions, with the published evidence and its limits for each.
Free to start
- Create your account & upload 23andMe or AncestryDNA
- Your genome overview — genes analyzed, variants found
- Delete your data anytime (export via support)
- THC metabolism profile and clearance speed
- CBD metabolism and metabolite ratios
- CYP3A5 + CYP2C19 genotype context
Decode
$59 one-time- THC metabolism via CYP2C9 with clinical evidence
- CBD metabolism via CYP2C19 with metabolite context
- CYP3A5 + CYP2C19 genotype context, with the study's limits stated
- CYP1A2 smoking interaction with affected medications
- Published research citations for every finding
- Plus medications, carrier status, nutrition, ancestry & the AI assistant
Cannabis Pharmacogenomics from DNA You Already Have
Decode uses raw data from 23andMe or AncestryDNA — free to start, then a one-time $59 you own for life. No new sample needed — we analyze the same CYP enzyme variants already in your uploaded file.
This is the same pharmacogenomic science used for FDA-approved medications. The CYP2C9-THC and CYP2C19-CBD relationships are published in peer-reviewed clinical pharmacology journals.
Based on Published Clinical Research
Every finding cites peer-reviewed studies on cannabinoid pharmacogenomics, and says how strong that evidence is. The CYP2C9-THC relationship comes from clinical pharmacokinetic work and is the best supported. The CYP3A5 and CYP2C19 findings come from a single small 2026 study whose authors concluded that pharmacogenomic testing may hold questionable utility for predicting CBD side effects — we report that alongside the result rather than omitting it.
For educational and informational purposes only. Decode does not recommend or endorse cannabis use. See our limitations page for details.
Ready to See Your Cannabis & CBD Results?
Upload your 23andMe or AncestryDNA raw data and read your results inside Decode. Free to start — then $59 one-time, yours for life.